Based on the key measurements obtained from Predictive Oncology's financial statements, Predictive Oncology is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. As of now, Predictive Oncology's Cash And Short Term Investments are increasing as compared to previous years. The Predictive Oncology's current Common Stock Total Equity is estimated to increase to about 275.4 K, while Total Assets are projected to decrease to under 9.5 M. Key indicators impacting Predictive Oncology's financial strength include:
The essential information of the day-to-day investment outlook for Predictive Oncology includes many different criteria found on its balance sheet. An individual investor should monitor Predictive Oncology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Predictive Oncology.
Predictive Oncology competes with GlucoTrack, Sharps Technology, Microbot Medical, Nexgel, and Pro Dex. Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Comparative valuation techniques use various fundamental indicators to help in determining Predictive Oncology's current stock value. Our valuation model uses many indicators to compare Predictive Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Predictive Oncology competition to find correlations between indicators driving Predictive Oncology's intrinsic value. More Info.
Predictive Oncology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Predictive Oncology's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Predictive Oncology's earnings, one of the primary drivers of an investment's value.
Predictive Oncology Systematic Risk
Predictive Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Predictive Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Predictive Oncology correlated with the market. If Beta is less than 0 Predictive Oncology generally moves in the opposite direction as compared to the market. If Predictive Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Predictive Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Predictive Oncology is generally in the same direction as the market. If Beta > 1 Predictive Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Predictive Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Predictive Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Predictive Oncology growth as a starting point in their analysis.
Predictive Oncology March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Predictive Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Predictive Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Predictive Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Predictive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Predictive Oncology's daily price indicators and compare them against related drivers.
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.